Cardiovascular disease is the leading cause of death in people living with type 2 diabetes.
Since concerns were highlighted with rosiglitazone, it was made mandatory for all new diabetes drugs to prove their cardiovascular safety. Somewhat unexpectedly, not only was cardiovascular safety established with certain newer diabetes drugs but also cardiovascular superiority compared to placebo i.e. significant reductions in major adverse cardiovascular events.
This webinar will summarise key take-home messages from all the published diabetes cardiovascular outcome studies to date, how these studies have changed guidelines and what the implications are for primary care.
Delivery of this webinar is supported by Data4NHS.
Co-produced by Best Practice and PCCS.
Should you have difficulties viewing the live webinar please try the following in order:
• Refresh your web page
• Exit the webinar and re-join
• Try a different browser
• Try dialling in to listen with a phone - UK dial in number is: +44 1793 250421
Please register for this Webinar to view the dial-in info.
GP Partner, GP with Specialist Interest in Diabetes & Medical Education
Kevin is a part-time GP Partner & GP Educational Supervisor working at the coalface in North Berwick Health Centre, near Edinburgh. Kevin is also Scottish lead of the Primary Care Diabetes Society and an observer member of the Primary Care...